Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 28984

    +

    15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor (ID 377)

    12:30 - 13:00  |  Author(s): ANTONIETA Salud
    • Abstract
    • Slides

    Background
    

    Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to have a worse prognosis and to lack epidermal growth factor receptor (EGFR) mutations. The aim of this study was to analyse the prognostic significance of TTFI status in a series of tumor samples from patients with clinically confirmed lung adenocarcinoma.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    A real-world data study of TTF1-negative ADC was performed in all lung cancer patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, using TTF1 clone 8G7G3/1(DAKO^®). Each patient’s clinical history, pathology specimens and molecular results were noted. The control group consisted of 231 patients with TTF1 positive lung ADC .

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    Three hundred and thirty four (334) patients with ADC were identified; TTF1 results were available in 258 (77,2%) cases. Of these, 27 (10,4%) patients were identified with TTF1-negative ADC (74% males). The median age of these patients was 66 years and their smoking history was as follows: 55,5% former smoker, 29,6% ex smokers and 14,8% never smokers. The clinical stages were as follows: stage I or II (n = 3 [11%]), stage III (n = 4 [14,8%]) and stage IV (n = 20 [74%]). Patients’ mean survival was 7,6 vs 24,4 months in ADC TTF1-negative patients versus TTF1-postive patients (P = 0,00001). When compared with the control group, TTF1-negative patients had shorter overall survival (P = 0,00001), regardless of whether patients were treated with radical or palliative intent: 34,4 vs 10, months P = 0,00001 (radical treatment) and 14,6 vs 6,7 months P = 0,007 (palliative intent). EGFR mutations were less frequent (P = 0,046) in TTF-negative tumors compared to the control group (5,5% vs 25,3%).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    Patients with TTF1-negative NSCLC ADC have worse overall survival, regardless of treatment intention, and a lower frequency of EGFR mutations.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    The authors.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.